Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, outlines the spleen volume responses as assessed in the JAKARTA study (NCT01437787), where patients with myelofibrosis were treated with fedratinib, a JAK inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).